Protalix BioTherapeutics Inc (PLX) — Titan Protect Analysis

PLX

Protalix BioTherapeutics Inc

Healthcare · ·

$1.99

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$158M

Total market value of the company

Trailing P/E

10.32

Reasonably valued

Forward P/E

3.16

Based on estimated future earnings — lower means cheaper

Rev Growth

+233.7%

Year-over-year revenue change

Profit Margin

20.1%

How much profit the company keeps from each dollar of revenue

ROE

27.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+453% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Protalix BioTherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial fo

https://www.protalix.com

Country: United States Employees: 226 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.757

Good returns relative to risk taken

Kelly Fraction

-0.0138

No positive edge detected — the data suggests staying out

Calmar Ratio

0.548

Acceptable balance between returns and drawdown risk

Annual Return

30.7%

Historical annualised return based on price data

Max Drawdown

-56.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.01

Very low correlation to market moves

52W High

$3.19

38% below the year high

52W Low

$1.32

51% above the year low

Avg Volume

864,574

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.19

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.62

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

45.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

62.7%

Profit from core operations before interest and tax

Free Cash Flow

$7M

Positive — the business generates more cash than it spends

Revenue (TTM)

$76M

Total revenue over the last 12 months

Net Income

$15M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$11.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go